• Citer

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

par Zardavas, Dimitros ;Fumagalli, Debora ;Loi, Sherene
Référence Current opinion in oncology, 24, 6, page (623-634)
Publication Publié, 2012-11

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Auteur:	Zardavas, Dimitros; Fumagalli, Debora; Loi, Sherene
Informations sur la publication:	Current opinion in oncology, 24, 6, page (623-634)
Statut de publication:	Publié, 2012-11
Sujet CREF:	Sciences biomédicales
	Cancérologie
MeSH keywords:	Antineoplastic Agents -- pharmacology -- therapeutic use
	Breast Neoplasms -- drug therapy -- genetics -- metabolism
	Clinical Trials as Topic
	Drug Resistance, Neoplasm
	Female
	Humans
	Phosphatidylinositol 3-Kinases -- antagonists & inhibitors -- genetics -- metabolism
	Protein Kinase Inhibitors -- pharmacology -- therapeutic use
	Receptor, erbB-2 -- metabolism
	Receptors, Estrogen -- metabolism
	Signal Transduction -- drug effects
	Sirolimus -- pharmacology -- therapeutic use
	TOR Serine-Threonine Kinases -- antagonists & inhibitors -- metabolism
Note générale:	Journal Article
	Research Support, Non-U.S. Gov't
	Review
	SCOPUS: re.j
Langue:	Anglais
Identificateurs:	urn:issn:1040-8746
	info:doi/10.1097/CCO.0b013e328358a2b5
	info:scp/84868212708
	info:pmid/22960556